Interleukin Genetics has released a new inflammation management program for patients at elevated risk for severe periodontitis.
The program, called Ilustra, replaces the company's PerioPredict brand. It is offered as an employee benefit or through insurance carriers to help manage chronic inflammation in patients who have a genetic tendency to overproduce inflammation, the company said.
The program includes a genetic test, educational outreach to the patient's care team, and reminders and content for patients, according to the company.
